Wound Therapy Firm Pushes For More Flexibility In Coverage-With-Evidence Conditions

CMS recently proposed to lift a long-established non-coverage policy for platelet-rich plasma wound therapy, but only for patients enrolled in a randomized trial. Manufacturer Cytomedix says a registry-based observational study would be a better approach.